
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC

Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
FDA Approves Aurlumyn FDA Approves Aurlumyn (iloprost) as the First Medication to Treat Severe Frostbite February 14, 2024 -- The U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce th
Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administ
Brain Cancer Risk Increased After Moderate/Severe, Penetrating TBI FRIDAY, Feb. 16. 2024 -- Moderate/severe and penetrating traumatic brain injury (TBI) are associated with an increased risk for subsequent development of brain cancer, according to a stud